AssetMark Inc’s Protagonist Therapeutics PTGX Stock Holding History

AssetMark Inc’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.1M	Buy	99,941 +1,254	+1%	+$179K	0.02%	485
2026 Q2	$12.1M	Buy	98,687 +52,245	+112%	+$5.46M	0.02%	512
2026 Q1	$4.89M	Buy	46,442 +46,157	+16,195%	+$4.09M	0.01%	667
2025 Q4	$24.9K	Buy	285 +5	+2%	+$409	﹤0.01%	1932
2025 Q3	$18.6K	Sell	280 -10	-3%	-$568	﹤0.01%	1940
2025 Q2	$16K	Sell	290 -5	-2%	-$240	﹤0.01%	1857
2025 Q1	$14.3K	Buy	295 +50	+20%	+$2.1K	﹤0.01%	1772
2024 Q4	$9.46K	Buy	245 +80	+48%	+$3.49K	﹤0.01%	1800
2024 Q3	$7.42K	Buy	+165	New	+$6.67K	﹤0.01%	1674
2018 Q1	–	Sell	-20	Closed	–	–	1857
2017 Q4	$0	Buy	+20	New	+$355	﹤0.01%	2074

Other funds holding PTGX

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

AssetMark Inc's PTGX Position: Q3 2026 in Review

AssetMark Inc increased its Protagonist Therapeutics (PTGX) stake by 1.3% in Q3 2026, buying an estimated $179K and bringing the position to 99,941 shares worth $14.1M. The position accounts for 0.02% of the portfolio, ranked #485.

AssetMark Inc first reported a position in PTGX in Q4 2017 and has held it in 10 quarters since. 89 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

AssetMark Inc held 99,941 shares of Protagonist Therapeutics worth $14.1M as of Q3 2026.
AssetMark Inc bought 1,254 Protagonist Therapeutics shares in Q3 2026, an estimated $179K.
Protagonist Therapeutics made up 0.02% of AssetMark Inc's portfolio in Q3 2026, its #485 holding.
AssetMark Inc first reported a position in Protagonist Therapeutics in Q4 2017 and has held it in 10 quarters since.
89 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.